SCHEMBL970573

SCHEMBL970573

CC(=O)Oc1cc2oc(-c3ccccc3)cc(=O)c2c(OCc2ccccc2)c1OC(C)=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREB1 P16220 3/20 0.63
ABCB1 P08183 3/20 0.59
MAPT P10636 2/20 0.59
PPARG P37231 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.54
BCHE P06276 1/20 0.54
ACHE P22303 1/20 0.54
KDM5A P29375 1/20 0.53
EGFR P00533 1/20 0.51
RET P07949 1/20 0.51
KDR P35968 1/20 0.51
ABL1 P00519 1/20 0.51
ABCG2 Q9UNQ0 1/20 0.50
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
CYP3A4 P08684 1/20 0.49
HPGD P15428 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HSD17B10 Q99714 1/20 0.49
PTPN1 P18031 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL970006 0.93 CREB1 (0.61) CREB1ABCB1MAPTPPARGL3MBTL1
SCHEMBL971866 0.92 CREB1 (0.73) CREB1ABCB1MAPTPPARGL3MBTL1
SCHEMBL972738 0.89 CREB1 (0.70) CREB1ABCB1MAPTABCG2KDM4E
SCHEMBL21515197 0.87 L3MBTL1 (0.62) CREB1ABCB1MAPTPPARGL3MBTL1
SCHEMBL971180 0.85 CREB1 (0.66) CREB1ABCB1MAPTABCG2KDM4E
SCHEMBL970574 0.84 CREB1 (0.64) CREB1ABCB1MAPTPPARGABCG2
SCHEMBL972837 0.83 CREB1 (0.80) CREB1ABCB1MAPTL3MBTL1ABCG2
SCHEMBL30852834 0.82 ABCB1 (0.65) CREB1ABCB1MAPTPPARGL3MBTL1
SCHEMBL974333 0.81 ABCB1 (0.68) CREB1ABCB1MAPTACHEABCG2
SCHEMBL30852784 0.81 CREB1 (0.77) CREB1ABCB1MAPTPPARGL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875650-B2 Baicalein analogs; enhances bioavailability of active compounds, especially orally administered compounds, by inhibition of P-glycoprotein 170 (P-gp 170) and/or CYP450 enzyme; 6-Acetoxy-5,7-dihydroxyflavone YALE UNIVERSITY (US) 2011-01-25 US disclosed
US-20070161605-A1 Compounds and methods to increase anti-p-glycoprotein activity of baicalein by alkylation on the a ring YALE UNIVERSITY (US) 2007-07-12 US disclosed
WO-2005075449-A1 COMPOUNDS AND METHODS TO INCREASE ANTI-P-GLYCOPROTEIN ACTIVITY OF BAICALEIN BY ALKYLATION ON THE A RING YALE UNIVERSITY (US) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161605-A1 Compounds and methods to increase anti-p-glycoprotein activity of baicalein by alkylation on the a ring ABCB1, ABCB11, ABCG2 CREB1 2524/4885ABCB1 1/4885MAPT 4867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.